Get the Stockscreener App
4.75
4.40%
+0.20
After Hours:
4.75
Annexon Inc stock is currently priced at $4.75, with a 24-hour trading volume of 2.90M.
It has seen a +4.40% increased in the last 24 hours and a -28.36% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $4.58 pivot point. If it approaches the $4.89 resistance level, significant changes may occur.
Previous Close:
$4.55
Open:
$4.59
24h Volume:
2.90M
Market Cap:
$432.92M
Revenue:
-
Net Income/Loss:
$-134.24M
P/E Ratio:
-2.399
EPS:
-1.98
Net Cash Flow:
$-121.34M
1W Performance:
+6.74%
1M Performance:
-28.36%
6M Performance:
+97.92%
1Y Performance:
-12.84%
1D Range:
$4.47
$4.85
52W Range:
$1.57
$8.40
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
650-822-5500
Address
180 Kimball Way, 2nd Floor Suite 200, South San Francisco
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Annexon (ANNX) to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research
Down -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX)
Zacks Investment Research
Are Medical Stocks Lagging Annexon (ANNX) This Year?
Zacks Investment Research
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to Know
Zacks Investment Research
What Makes Annexon (ANNX) a New Buy Stock
Zacks Investment Research
Annexon Inc Stock (ANNX) Financials Data
Annexon Inc (ANNX) Net Income 2024
ANNX net income (TTM) was -$134.24 million for the quarter ending December 31, 2023, a +5.43% increase year-over-year.
Annexon Inc (ANNX) Cash Flow 2024
ANNX recorded a free cash flow (TTM) of -$121.33 million for the quarter ending December 31, 2023, a +1.22% increase year-over-year.
Annexon Inc (ANNX) Earnings per Share 2024
ANNX earnings per share (TTM) was -$1.77 for the quarter ending December 31, 2023, a +38.33% growth year-over-year.
About Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.
3.18%
Cap:
|
Volume (24h):